IGC Pharma, Inc.
IGC · XNYSCIK 1326205fmd_1DF5XKQNRZ8PCVMT6PXT7G367FManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Sep 30, 2026, 66 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 6 | 1 | 2 | 5 | 4 | 1 | 0 | 1 | 1 | 1 |
| Cost of revenue | 6 | 0 | 2 | 5 | 4 | 1 | 0 | 0 | 1 | 1 |
| Gross profit | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Research and development | – | – | 0 | 1 | 1 | 1 | 2 | 3 | 4 | 4 |
| Selling, general and administrative | 3 | 2 | 2 | 4 | 6 | 8 | 13 | 9 | 7 | 4 |
| Operating income | (3) | (2) | (2) | (5) | (7) | (9) | (15) | (12) | (10) | (7) |
| Interest expense | 0 | 0 | 0 | – | – | 0 | 0 | 0 | 0 | 0 |
| Interest and investment income | 0 | 0 | 0 | – | – | – | – | – | – | – |
| Other non-operating income (expense) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before taxes | (3) | (2) | (2) | (4) | (7) | (9) | (15) | (12) | (13) | (7) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (3) | (2) | (2) | (4) | (7) | (9) | (15) | (12) | (13) | (7) |
| Net income | (3) | (2) | (2) | (4) | (7) | (9) | (15) | (12) | (13) | (7) |